References
- 1KurlanRMcDermottMPDeeleyCComoPGBrowerCEapenSet alPrevalence of tics in schoolchildren and association with placement in special educationNeurology2001571383138810.1212/WNL.57.8.138311673576
- 2PiacentiniJWoodsDWScahillLWilhelmSPetersonALChangSet alBehavior therapy for children with Tourette disorder: a randomized controlled trialJAMA20103031929193710.1001/jama.2010.60720483969
- 3HamaniCSaint-CyrJAFraserJKaplittMLozanoAMThe subthalamic nucleus in the context of movement disordersBrain2004127(Pt 142010.1093/brain/awh02914607789
- 4MoriFOkadaKNomuraTKobayashiYThe pedunculopontine tegmental nucleus as a motor and cognitive interface between the cerebellum and basal gangliaFront Neuroanat20161010910.3389/fnana.2016.0010927872585
- 5HooksBMMaoTGutniskyDAYamawakiNSvobodaKShepherdGMOrganization of cortical and thalamic input to pyramidal neurons in mouse motor cortexJ Neurosci20133374876010.1523/JNEUROSCI.4338-12.201323303952
- 6AllowayKDSmithJBMoweryTMWatsonGDRSensory processing in the dorsolateral striatum: the contribution of thalamostriatal pathwaysFront Syst Neurosci2017115310.3389/fnsys.2017.0005328790899
- 7AlbinRLYoungABPenneyJBThe functional anatomy of basal ganglia disordersTrends Neurosci19891236637510.1016/0166-2236(89)90074-X2479133
- 8CuiGJunSBJinXPhamMDVogelSSLovingerDMet alConcurrent activation of striatal direct and indirect pathways during action initiationNature201349423824210.1038/nature1184623354054
- 9CazorlaMKangUJKellendonkCBalancing the basal ganglia circuitry: a possible new role for dopamine D2 receptors in health and diseaseMov Disord20153089590310.1002/mds.2628226018615
- 10HegemanDJHongESHernandezVMChanCSThe external globus pallidus: progress and perspectivesEur J Neurosci2016431239126510.1111/ejn.1319626841063
- 11SchmidtRBerkeJDA Pause-then-cancel model of stopping: evidence from basal ganglia neurophysiologyPhilos Trans R Soc Lond B Biol Sci2017372171810.1098/rstb.2016.0202
- 12MalletNSchmidtRLeventhalDChenFAmerNBoraudTet alArkypallidal cells send a stop signal to striatumNeuron20168930831610.1016/j.neuron.2015.12.01726777273
- 13HarrisELSchuerholzLJSingerHSReaderMJBrownJECoxCet alExecutive function in children with Tourette syndrome and/or attention deficit hyperactivity disorderJ Int Neuropsychol Soc1995151151610.1017/S13556177000006319375237
- 14SchuerholzLJSingerHSDencklaMBGender study of neuropsychological and neuromotor function in children with Tourette syndrome with and without attention-deficit hyperactivity disorderJ Child Neurol19981327728210.1177/0883073898013006079660511
- 15SternERBlairCPetersonBSInhibitory deficits in Tourette’s syndromeDev Psychobiol20085091810.1002/dev.2026618085554
- 16HirschtrittMELeePCPaulsDLDionYGradosMAIllmannCet alLifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndromeJAMA Psychiatry20157232533310.1001/jamapsychiatry.2014.265025671412
- 17LehericySDucrosMKrainikAFrancoisCVan de MoortelePFUgurbilKet al3-D diffusion tensor axonal tracking shows distinct SMA and pre-SMA projections to the human striatumCereb Cortex2004141302130910.1093/cercor/bhh09115166103
- 18MinzerKLeeOHongJJSingerHSIncreased prefrontal D2 protein in Tourette syndrome: a postmortem analysis of frontal cortex and striatumJ Neurol Sci2004219556110.1016/j.jns.2003.12.00615050438
- 19YoonDYGauseCDLeckmanJFSingerHSFrontal dopaminergic abnormality in Tourette syndrome: a postmortem analysisJ Neurol Sci2007255505610.1016/j.jns.2007.01.06917337006
- 20PetersonBSStaibLScahillLZhangHAndersonCLeckmanJFet alRegional brain and ventricular volumes in Tourette syndromeArch Gen Psychiatry20015842744010.1001/archpsyc.58.5.42711343521
- 21Muller-VahlKRKaufmannJGrosskreutzJDenglerREmrichHMPeschelTPrefrontal and anterior cingulate cortex abnormalities in Tourette syndrome: evidence from voxel-based morphometry and magnetization transfer imagingBMC Neurosci2009104710.1186/1471-2202-10-4719435502
- 22KalanithiPSZhengWKataokaYDiFigliaMGrantzHSaperCBet alAltered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndromeProc Natl Acad Sci USA2005102133071331210.1073/pnas.050262410216131542
- 23KataokaYKalanithiPSGrantzHSchwartzMLSaperCLeckmanJFet alDecreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndromeJ Comp Neurol201051827729110.1002/cne.2220619941350
- 24MahoneEMCrocettiDTochenLKlineTMostofskySHSingerHSAnomalous putamen volume in children with complex motor stereotypiesPediatr Neurol201665596310.1016/j.pediatrneurol.2016.08.02327751663
- 25SingerHSReissALBrownJEAylwardEHShihBCheeEet alVolumetric MRI changes in basal ganglia of children with Tourette’s syndromeNeurology19934395095610.1212/WNL.43.5.9508492951
- 26PetersonBSThomasPKaneMJScahillLZhangHBronenRet alBasal Ganglia volumes in patients with Gilles de la Tourette syndromeArch Gen Psychiatry20036041542410.1001/archpsyc.60.4.41512695320
- 27PogorelovVXuMSmithHRBuchananGFPittengerCCorticostriatal interactions in the generation of tic-like behaviors after local striatal disinhibitionExp Neurol201526512212810.1016/j.expneurol.2015.01.00125597650
- 28WorbeYBaupNGrabliDChaigneauMMounayarSMcCairnKet alBehavioral and movement disorders induced by local inhibitory dysfunction in primate striatumCereb Cortex2009191844185610.1093/cercor/bhn21419068490
- 29WorbeYSgambato-FaureVEpinatJChaigneauMTandeDFrancoisCet alTowards a primate model of Gilles de la Tourette syndrome: anatomo-behavioural correlation of disorders induced by striatal dysfunctionCortex2013491126114010.1016/j.cortex.2012.08.02023040317
- 30BronfeldMYaelDBelelovskyKBar-GadIMotor tics evoked by striatal disinhibition in the ratFront Syst Neurosci201375010.3389/fnsys.2013.0005024065893
- 31Bosch-BoujuCHylandBIParr-BrownlieLCMotor thalamus integration of cortical, cerebellar and basal ganglia information: implications for normal and parkinsonian conditionsFront Comput Neurosci2013716310.3389/fncom.2013.0016324273509
- 32BourLJAckermansLFonckeEMCathDvan der LindenCVisser VandewalleVet alTic related local field potentials in the thalamus and the effect of deep brain stimulation in Tourette syndrome: Report of three casesClin Neurophysiol20151261578158810.1016/j.clinph.2014.10.21725435514
- 33McCairnKWIrikiAIsodaMGlobal dysrhythmia of cerebro-basal ganglia-cerebellar networks underlies motor tics following striatal disinhibitionJ Neurosci20133369770810.1523/JNEUROSCI.4018-12.201323303948
- 34CaligioreDMannellaFArbibMABaldassarreGDysfunctions of the basal ganglia-cerebellar-thalamo-cortical system produce motor tics in Tourette syndromePLoS Comput Biol201713e100539510.1371/journal.pcbi.100539528358814
- 35Garcia-CabezasMARicoBSanchez-GonzalezMACavadaCDistribution of the dopamine innervation in the macaque and human thalamusNeuroimage20073496598410.1016/j.neuroimage.2006.07.03217140815
- 36García-CabezasMÁMartínez-SánchezPSánchez-GonzálezMÁGarzónMCavadaCDopamine innervation in the thalamus: monkey versus ratCereb Cortex20091942443410.1093/cercor/bhn09318550594
- 37GovindaiahGWangYCoxCLDopamine enhances the excitability of somatosensory thalamocortical neuronsNeuroscience201017098199110.1016/j.neuroscience.2010.08.04320801197
- 38IchinoseTTanimotoHYamagataNBehavioral modulation by spontaneous activity of dopamine neuronsFront Syst Neurosci2017118810.3389/fnsys.2017.0008829321731
- 39NelsonAJKillcrossSAccelerated habit formation following amphetamine exposure is reversed by D1, but enhanced by D2, receptor antagonistsFront Neurosci201377610.3389/fnins.2013.0007623720609
- 40NelsonABHammackNYangCFShahNMSealRPKreitzerACStriatal cholinergic interneurons Drive GABA release from dopamine terminalsNeuron201482637010.1016/j.neuron.2014.01.02324613418
- 41BuseJSchoenefeldKMunchauARoessnerVNeuromodulation in Tourette syndrome: dopamine and beyondNeurosci Biobehav Rev2013371069108410.1016/j.neubiorev.2012.10.00423085211
- 42SwerdlowNRUpdate: studies of prepulse inhibition of startle, with particular relevance to the pathophysiology or treatment of Tourette syndromeNeurosci Biobehav Rev2013371150115610.1016/j.neubiorev.2012.09.00223017868
- 43GraybielAMHabits, rituals, and the evaluative brainAnnu Rev Neurosci20083135938710.1146/annurev.neuro.29.051605.11285118558860
- 44ColwillRMRescorlaRAEffect of reinforcer devaluation on discriminative control of instrumental behaviorJ Exp Psychol Anim Behav Process199016404710.1037/0097-7403.16.1.402303793
- 45SingerHSTuneLEButlerIJZaczekRCoyleJTClinical symptomatology, CSF neurotransmitter metabolites, and serum haloperidol levels in Tourette syndromeAdv Neurol1982351771836959488
- 46RiddleMALeckmanJFAndersonGMOrtSIHardinMTStevensonJet alTourette’s syndrome: clinical and neurochemical correlatesJ Am Acad Child Adolesc Psychiatry19882740941210.1097/00004583-198807000-000043182595
- 47SingerHSHahnIHMoranTHAbnormal dopamine uptake sites in postmortem striatum from patients with Tourette’s syndromeAnn Neurol19913055856210.1002/ana.4103004081838678
- 48ErnstMZametkinAJJonsPHMatochikJAPascualvacaDCohenRMHigh presynaptic dopaminergic activity in children with Tourette’s disorderJ Am Acad Child Adolesc Psychiatry199938869410.1097/00004583-199901000-000249893421
- 49RabeyJMObermanZGraffEKorczynADDecreased dopamine uptake into platelet storage granules in Gilles de la Tourette diseaseBiol Psychiatry19953811211510.1016/0006-3223(94)00234-T7578642
- 50MaiaTVConceicaoVAThe roles of phasic and tonic dopamine in tic learning and expressionBiol Psychiatry20178240141210.1016/j.biopsych.2017.05.02528734459
- 51SteevesTDKoJHKideckelDMRusjanPHouleSSandorPet alExtrastriatal dopaminergic dysfunction in Tourette syndromeAnn Neurol20106717018110.1002/ana.2180920225192
- 52SingerHSSzymanskiSGiulianoJYokoiFDoganASBrasicJRet alElevated intrasynaptic dopamine release in Tourette’s syndrome measured by PETAm J Psychiatry20021591329133610.1176/appi.ajp.159.8.132912153825
- 53DenysDde VriesFCathDFigeeMVulinkNVeltmanDJet alDopaminergic activity in Tourette syndrome and obsessive-compulsive disorderEur Neuropsychopharmacol2013231423143110.1016/j.euroneuro.2013.05.01223876376
- 54MogwitzSBuseJWolffNRoessnerVUpdate on the pharmacological treatment of tics with dopamine-modulating agentsACS Chem Neurosci2018965167210.1021/acschemneuro.7b0046029498507
- 55QuezadaJCoffmanKACurrent approaches and new developments in the pharmacological management of Tourette syndromeCNS Drugs201832334510.1007/s40263-017-0486-029335879
- 56GilbertDLBudmanCLSingerHSKurlanRChipkinREA D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndromeClin Neuropharmacol201437263010.1097/WNF.000000000000001724434529
- 57GilbertDLMurphyTKJankovicJBudmanCLBlackKJKurlanRMet alEcopipam, a D1 receptor antagonist, for treatment of Tourette syndrome in children: a randomized, placebo-controlled crossover studyMov Disord cited2018331272128010.1002/mds.27457
- 58NicolsonRCraven-ThussBSmithJMckinlayBDCastellanosFXA randomized, double-blind, placebo-controlled trial of metoclopramide for the treatment of Tourette’s disorderJ Am Acad Child Adolesc Psychiatry20054464064610.1097/01.chi.0000163279.39598.4415968232
- 59Müller-VahlKRKruegerDDoes Tourette syndrome prevent tardive dyskinesia?Move Disord2011262442244310.1002/mds.23894
- 60KurlanRCrespiGCoffeyBMueller-VahlKKovalSWunderlichGet alA multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette’s syndromeMov Disord20122777577810.1002/mds.2491922407510
- 61HarrisKSingerHSTic disorders: neural circuits, neurochemistry, and neuroimmunologyJ Child Neurol20062167868910.1177/0883073806021008090116970869
- 62NaaijenJFordeNJLythgoeDJAkkermansSEOpenneerTJDietrichAet alFronto-striatal glutamate in children with Tourette’s disorder and attention-deficit/hyperactivity disorderNeuroimage Clin201713162310.1016/j.nicl.2016.11.013
- 63KanaanASGeraschSGarcia-GarciaILampeLPampelAAnwanderAet alPathological glutamatergic neurotransmission in Gilles de la Tourette syndromeBrain201714021823410.1093/brain/aww28528007998
- 64HarrisADSingerHSHorskaAKlineTRyanMEdden RaE, et al. GABA and glutamate in children with primary complex motor stereotypies: an 1H-MRS study at 7TAJNR Am J Neuroradiol201637552710.3174/ajnr.A454726542237
- 65RothmanDLPetroffOABeharKLMattsonRHLocalized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivoProc Natl Acad Sci USA1993905662566610.1073/pnas.90.12.56628516315
- 66FaureAHaberlandUCondeFEl MassiouiNLesion to the nigrostriatal dopamine system disrupts stimulus-response habit formationJ Neurosci2005252771278010.1523/JNEUROSCI.3894-04.200515772337
- 67FaureALeblanc-VeyracPEl MassiouiNDopamine agonists increase perseverative instrumental responses but do not restore habit formation in a rat model of ParkinsonismNeuroscience201016847748610.1016/j.neuroscience.2010.03.04720362642
- 68BurtonFHBack to the future: circuit-testing TS & OCDJ Neurosci Methods201729221110.1016/j.jneumeth.2017.07.02528756273
- 69KushnerMGKimSWDonahueCThurasPAdsonDKotlyarMet alD-cycloserine augmented exposure therapy for obsessive-compulsive disorderBiol Psychiatry20076283583810.1016/j.biopsych.2006.12.02017588545
- 70LemmonMEGradosMKlineTThompsonCBAliSFSingerHSEfficacy of glutamate modulators in tic suppression: a double-blind, randomized control trial of d-serine and riluzole in Tourette syndromePediatr Neurol20155262963410.1016/j.pediatrneurol.2015.02.00226002052
- 71BlochMHPanzaKEYaffaAAlvarengaPGJakubovskiEMulqueenJMet alN-Acetylcysteine in the treatment of pediatric Tourette syndrome: randomized, double-blind, placebo-controlled add-on trialJ Child Adolesc Psychopharmacol20162632733410.1089/cap.2015.010927027204
- 72ShinomuraTNakaoSAdachiTShinguKClonidine inhibits and phorbol acetate activates glutamate release from rat spinal synaptoneurosomesAnesth Analg1999881401140510.1213/00000539-199906000-0003710357352
- 73JellishWSMurdochJKindelGZhangXWhiteFAThe effect of clonidine on cell survival, glutamate, and aspartate release in normo- and hyperglycemic rats after near complete forebrain ischemiaExp Brain Res200516752653410.1007/s00221-005-0064-416044300
- 74WangYLiuJGuiZHAliUFanLLHouCet alalpha2-Adrenoceptor regulates the spontaneous and the GABA/glutamate modulated firing activity of the rat medial prefrontal cortex pyramidal neuronsNeuroscience201118219320210.1016/j.neuroscience.2011.03.01621402127
- 75CreedMCNtamatiNRTanKRVTA GABA neurons modulate specific learning behaviors through the control of dopamine and cholinergic systemsFront Behav Neurosci20148810.3389/fnbeh.2014.0000824478655
- 76LernerABagicASimmonsJMMariZBonneOXuBet alWidespread abnormality of the gamma-aminobutyric acid-ergic system in Tourette syndromeBrain2012135(Pt 61926193610.1093/brain/aws10422577221
- 77GilbertDLBansalASSethuramanGSalleeFRZhangJLippsTet alAssociation of cortical disinhibition with tic, ADHD, and OCD severity in Tourette syndromeMov Disord20041941642510.1002/mds.2004415077239
- 78McCairnKWNagaiYHoriYNinomiyaTKikuchiELeeJYet alA primary role for nucleus accumbens and related limbic network in vocal ticsNeuron20168930030710.1016/j.neuron.2015.12.02526796690
- 79AwaadYTics in Tourette syndrome: new treatment optionsJ Child Neurol19991431631910.1177/08830738990140050810342599
- 80DrtílkováIBalaštíkováBLemanováHŽákJTherapeutical effects of clonidine and clonazepam in children with tick syndromeHomeost Health Dis199435296
- 81MerikangasJRMerikangasKRKoppUHaninIBlood choline and response to clonazepam and haloperidol in Tourette’s syndromeActa Psychiatr Scand7239539910.1111/j.1600-0447.1985.tb02628.x
- 82CavannaAENaniAAntiepileptic drugs and Tourette syndromeMartinoDCavannaAEInternational review of neurobiology (Advances in the neurochemistry and neuropharmacology of Tourette syndrome, vol. 112).Cambridge, MAAcademic Pressp 373389Available from: http://www.sciencedirect.com/science/article/pii/B9780124115460000123
- 83JankovicJJimenez-ShahedJBrownLWA randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndromeJ Neurol Neurosurg Psychiatry201081707310.1136/jnnp.2009.18534819726418
- 84YangC-SZhangL-LZengL-NHuangLLiuY-TTopiramate for Tourette’s syndrome in children: a meta-analysisPediatr Neurol20134934435010.1016/j.pediatrneurol.2013.05.00224139534
- 85AwaadYMichonAMMinarikSUse of levetiracetam to treat tics in children and adolescents with Tourette syndromeMove Disord2071471810.1002/mds.20385
- 86Smith-HicksCL1BridgesDDPaynterNPSingerHSA double blind randomized placebo control trial of levetiracetam in Tourette syndromeMov Disord2007221764177010.1002/mds.2161517566124
- 87HedderickEFMorrisCMSingerHSDouble-blind, crossover study of clonidine and levetiracetam in Tourette syndromePediatr Neurol20094042042510.1016/j.pediatrneurol.2008.12.01419433274
- 88GobertARivetJMAudinotVNewman-TancrediACistarelliLMillanMJSimultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of releaseNeuroscience19988441342910.1016/S0306-4522(97)00565-49539213
- 89SingerHSHahnIHKrowiakENelsonEMoranTTourette’s syndrome: a neurochemical analysis of postmortem cortical brain tissueAnn Neurol19902744344610.1002/ana.4102704151972320
- 90ChappellPRiddleMAndersonGScahillLHardinMWalkerDet alEnhanced stress responsivity of Tourette syndrome patients undergoing lumbar punctureBiol Psychiatry199436354310.1016/0006-3223(94)90060-48080901
- 91SingerHSTreatment of tics and Tourette syndromeCurr Treat Options Neurol20101253956110.1007/s11940-010-0095-420848326
- 92MurphyTKFernandezTVCoffeyBJRahmanOGavaletzAHanksCEet alExtended-release guanfacine does not show a large effect on tic severity in children with chronic tic disordersJ Child Adolesc Psychopharmacol20172776277010.1089/cap.2017.002428723227
- 93AlamoCLópez-MuñozFSánchez-GarcíaJMechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (ADHD)Actas Esp Psiquiatr20164410711227254403
- 94OgawaSKCohenJYHwangDUchidaNWatabe-UchidaMOrganization of monosynaptic inputs to the serotonin and dopamine neuromodulatory systemsCell Rep201481105111810.1016/j.celrep.2014.06.04225108805
- 95LuoXFZhangBLLiJCYangYYSunYFZhaoHLateral habenula as a link between dopaminergic and serotonergic systems contributes to depressive symptoms in Parkinson’s diseaseBrain Res Bull201511040610.1016/j.brainresbull.2014.11.00625499570
- 96NiensJRehFÇobanBCichewiczKEckardtJLiuY-Tet alDopamine modulates serotonin innervation in the drosophila brainFront Syst Neurosci2017117610.3389/fnsys.2017.0007629085286
- 97ZengB-YIravaniMMJacksonMJRoseSParentAJennerPMorphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesiaNeurobiol Dis20104059960710.1016/j.nbd.2010.08.00420713157
- 98ComingsDEBlood serotonin and tryptophan in Tourette syndromeAm J Med Genet19903641843010.1002/ajmg.13203604102389798
- 99ButlerIJKoslowSHSeifertWE
Jr CaprioliRMSingerHSBiogenic amine metabolism in Tourette syndromeAnn Neurol19796373910.1002/ana.410060109292354 - 100AndersonGMPollakESChatterjeeDLeckmanJFRiddleMACohenDJPostmortem analysis of subcortical monoamines and amino acids in Tourette syndromeAdv Neurol1992581231331414615
- 101HeinzAKnableMBWolfSSJonesDWGoreyJGHydeTMet alTourette’s syndrome: [I-123]beta-CIT SPECT correlates of vocal tic severityNeurology1998511069107410.1212/WNL.51.4.10699781531
- 102Muller-VahlKRMeyerGJKnappWHEmrichHMGielowPBruckeTet alSerotonin transporter binding in Tourette syndromeNeurosci Lett200538512012510.1016/j.neulet.2005.05.03115936877
- 103HaugbolSPinborgLHRegeurLHansenESBolwigTGNielsenFAet alCerebral 5-HT2A receptor binding is increased in patients with Tourette’s syndromeInt J Neuropsychopharmacol20071024525210.1017/S146114570600655916945163
- 104BehenMChuganiHTJuhaszCHelderEHoAMaqboolMet alAbnormal brain tryptophan metabolism and clinical correlates in Tourette syndromeMov Disord2007222256226210.1002/mds.2171217708557
- 105CanalCEBoothRGMorganDSupport for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response modelNeuropharmacology20137011212110.1016/j.neuropharm.2013.01.00723353901
- 106Nieto-AlamillaGMarquez-GomezRGarcia-GalvezAMMorales-FigueroaGEArias-MontanoJAThe histamine H3 receptor: structure, pharmacology, and functionMol Pharmacol20169064967310.1124/mol.116.10475227563055
- 107PanulaPNuutinenSThe histaminergic network in the brain: basic organization and role in diseaseNat Rev Neurosci20131447248710.1038/nrn352623783198
- 108HaasHLSergeevaOASelbachOHistamine in the nervous systemPhysiol Rev2008881183124110.1152/physrev.00043.200718626069
- 109EllenbroekBAHistamine H3 receptors, the complex interaction with dopamine and its implications for addictionBr J Pharmacol2013170465710.1111/bph.1222123647606
- 110Ercan-SencicekAGStillmanAAGhoshAKBilguvarKO’RoakBJMasonCEet alL-histidine decarboxylase and Tourette’s syndromeN Engl J Med20103621901190810.1056/NEJMoa090700620445167
- 111FernandezTVSandersSJYurkiewiczIRErcan-SencicekAGKimYSFishmanDOet alRare copy number variants in Tourette syndrome disrupt genes in histaminergic pathways and overlap with autismBiol Psychiatry20127139240210.1016/j.biopsych.2011.09.03422169095
- 112BolamJPEllenderTJHistamine and the striatumNeuropharmacology2016106748410.1016/j.neuropharm.2015.08.01326275849
- 113ChristopherPHistidine decarboxylase knockout mice as a model of the pathophysiology of Tourette syndrome and related conditionsHandb Exp Pharmacol201724118921510.1007/978-3-319-58194-128233179
- 114HartmannAWorbeYArnulfIIncreasing histamine neurotransmission in Gilles de la Tourette syndromeJ Neurol201225937537610.1007/s00415-011-6171-121779959
- 115Safety, tolerability, pharmacokinetic, and efficacy study of AZD5213 in adolescents with Tourette’s disorder – study resultsAvailable fromhttps://clinicaltrials.gov/ct2/show/results/NCT01904773(cited 2018 May 29)
- 116LicheriVLagströmOLotfiAPattonMHWigströmHMathurBet alComplex control of striatal neurotransmission by nicotinic acetylcholine receptors via excitatory inputs onto medium spiny neuronsJ Neurosci2018386597660710.1523/JNEUROSCI.0071-18.201829941445
- 117TannerCMGoetzCGKlawansHLCholinergic mechanisms in Tourette syndromeNeurology1982321315131710.1212/WNL.32.11.13156957735
- 118SingerHSOshidaLCoyleJTCSF cholinesterase activity in Gilles de la Tourette’s syndromeArch Neurol19844175675710.1001/archneur.1984.040501800780226588929
- 119XuMKobetsADuJCLenningtonJLiLBanasrMet alTargeted ablation of cholinergic interneurons in the dorsolateral striatum produces behavioral manifestations of Tourette syndromeProc Natl Acad Sci USA201511289389810.1073/pnas.141953311225561540
- 120BarbeauACholinergic treatment in the Tourette syndromeN Engl J Med19803021310131110.1056/NEJM198006053022313
- 121PolinskyRJEbertMHCaineEDLudlowCBassichCJCholinergic treatment in the Tourette syndromeN Engl J Med1980302131010.1056/NEJM198006053022313
- 122StahlSMBergerPAPhysostigmine in Tourette syndrome: evidence for cholinergic underactivityAm J Psychiatry198113824024210.1176/ajp.138.2.2406935977
- 123SilverAAShytleRDSanbergPRMecamylamine in Tourette’s syndrome: a two-year retrospective case studyJ Child Adolesc Psychopharmacol200010596810.1089/cap.2000.10.5910933116
- 124MouradianMMBraithwaiteSVoronkovMMethod of treating dyskinesiaUS20160151359A12016Available from: https://patents.google.com/patent/US20160151359A1/en?inventor = M.+Maral+Mouradian&sort = new(cited 2018 Jul 14).
- 125ObesoJAMerelloMRodríguez-OrozMCMarinCGuridiJAlvarezLLevodopa-induced dyskinesias in Parkinson’s diseaseKollerWCMelamedEHandbook of clinical neurology (Parkinson’s disease and related disorders, Part II; vol. 84).New YorkElsevier2007p 185218Available from: http://www.sciencedirect.com/science/article/pii/S0072975207840401(cited 2018 Jul 17).
- 126GeorgeSRVan LoonGRβ-endorphin alters dopamine uptake by the dopamine neurons of the hypothalamus and striatumBrain Res198224829330310.1016/0006-8993(82)90587-X6291701
- 127SandykRNaloxone abolishes obsessive-compulsive behavior in Tourette’s syndromeInt J Neurosci198735939410.3109/002074587089871153476477
- 128AtwoodBKKupferschmidtDALovingerDMOpioids induce dissociable forms of long-term depression of excitatory inputs to the dorsal striatumNat Neurosci20141754054810.1038/nn.365224561996
- 129BereczJMDyskenMWDavisJMNaloxone effect in Tourette syndromeNeurology197929(Part 1131610.1212/WNL.29.9_Part_1.1316-a289910
- 130HaberSNKowallNWVonsattelJPBirdEDRichardsonEPGilles de la Tourette’s syndrome: a postmortem neuropathological and immunohistochemical studyJ Neurolog Sci198675225224110.1016/0022-510X(86)90097-3
- 131LeckmanJFRiddleMABerrettiniWHAndersonGMHardinMChappellPet alElevated CSF dynorphin A [1-8] in Tourette’s syndromeLife Sci1988432015202310.1016/0024-3205(88)90575-92463450
- 132ElghabaRBracciEDichotomous effects of mu opioid receptor activation on striatal low-threshold spike interneuronsFront Cell Neurosci20171138510.3389/fncel.2017.0038529259544
- 133CapassoASorrentinoLDifferential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileumBr J Pharmacol19971201001100610.1038/sj.bjp.07009959134209
- 134AuffretMDrapierSVérinMThe many faces of apomorphine: lessons from the past and challenges for the futureDrugs R D201811710.1007/s40268-018-0230-3
- 135The dopamine receptor agonist 7-OH-DPAT modulates the acquisition and expression of morphine-induced place preferenceScienceDirectAvailable from: https://www.sciencedirect.com/science/article/pii/001429999400708F?via%3Dihub(cited 2018 May 21)
- 136
- 137LichterDMajumdarLKurlanROpiate withdrawal unmasks Tourette’s syndromeClin Neuropharmacol19881155956410.1097/00002826-198812000-000123233593
- 138TrescotAMDattaSLeeMHansenHOpioid pharmacologyPain Physician200811(Suppl)S13315318443637
- 139HilarioMRClouseEYinHHCostaRMEndocannabinoid signaling is critical for habit formationFront Integr Neurosci20071610.3389/neuro.07.006.200718958234
- 140Rodríguez-MuñozMSánchez-BlázquezPMerlosMGarzón-NiñoJEndocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunctionOncotarget20167558405586210.18632/oncotarget.1009527323834
- 141BerdingGMuller-VahlKSchneiderUGielowPFitschenJStuhrmannMet al[123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Delta9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in Tourette patientsBiol Psychiatry20045590491510.1016/j.biopsych.2004.01.00515110734
- 142MathewsCAScharfJMMillerLLMacdonald-WallisCLawlorDABen-ShlomoYAssociation between pre- and perinatal exposures and Tourette syndrome or chronic tic disorder in the ALSPAC cohortBr J Psychiatry2014204404510.1192/bjp.bp.112.12546824262815
- 143CeciCProietti OnoriMMacriSLaviolaGInteraction between the endocannabinoid and serotonergic system in the exhibition of head twitch response in four mouse strainsNeurotox Res20152727528310.1007/s12640-014-9510-z25516122
- 144Muller-VahlKRTreatment of Tourette syndrome with cannabinoidsBehav Neurol20132711912410.1155/2013/29426423187140
- 145WhitingPFWolffRFDeshpandeSDi NisioMDuffySHernandezAVet alCannabinoids for medical use: a systematic review and meta-analysisJAMA201531324567310.1001/jama.2015.635826103030
- 146Müller-VahlKRCannabinoids reduce symptoms of Tourette’s syndromeExpert Opin Pharmacother200341717172510.1517/14656566.4.10.171714521482
- 147KanaanASJakubovskiEMüller-VahlKSignificant tic reduction in an otherwise treatment-resistant patient with Gilles de la Tourette syndrome following treatment with nabiximolsBrain Sci201774710.3390/brainsci7050047
- 148TrainorDEvansLBirdRSevere motor and vocal tics controlled with Sativex®Australas Psychiatry20162454154410.1177/103985621666373727558217
- 149TurnerSEWilliamsCMIversenLWhalleyBJMolecular Pharmacology of PhytocannabinoidsProg Chem Org Nat Prod20171036110110.1007/978-3-319-45541-928120231
- 150NiesinkRJMRigterSKoeterMWBruntTMPotency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15Addiction20151101941195010.1111/add.1308226234170
- 151JikomesNZoorobMThe cannabinoid content of legal cannabis in Washington State varies systematically across testing facilities and popular consumer productsScientific Reports20188451910.1038/s41598-018-22755-229540728
- 152SpithoffSKahanMCannabis and Canadian youthCan Fam Physician20146078578725217667
- 153EvinsAEGreenAIKaneJMMurrayRMThe effect of marijuana use on the risk for schizophreniaJ Clin Psychiatry2012731463146810.4088/JCP.12012co1c23218162
- 1542018 Emerging Science AbstractsNeurology201890e2182
- 155HirjakDMeyer-LindenbergAFritzeSSambataroFKuberaKMWolfRCMotor dysfunction as research domain across bipolar, obsessive-compulsive and neurodevelopmental disordersNeurosci Biobehav Rev10.1016/j.neubiorev.2018.09.009
- 156MaiaTVConceiçãoVADopaminergic disturbances in Tourette syndrome: an integrative accountBiol Psychiatry20188433234410.1016/j.biopsych.2018.02.117229656800
- 157HienertMGryglewskiGStamenkovicMKasperSLanzenbergerRStriatal dopaminergic alterations in Tourette’s syndrome: a meta-analysis based on 16 PET and SPECT neuroimaging studiesTranslational Psychiatry2018814310.1038/s41398-018-0202-y30072700